| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Pediatric [C. A. F., C. C. K., G. D. C., L. J. H.] and Navy Medical Oncology [T. M., M. M. N.] Branches and Department of Pathology [M. T.], National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, and Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75235 [P. D. N., N. J. W.]
The p53 gene was examined in primary or metastatic tumors from six patients with rhabdomyosarcoma (RMS) and in five RMS cell lines by screening methods including single-strand conformation polymorphism analysis, the RNase protection assay, sequencing of complementary DNA subclones, and Southern blotting. Six original tumors were of embryonal histology, four alveolar, and one mixed. p53 mutations were identified in four of the six tumors or cell lines derived from tumors with embryonal histology and in one of the four with alveolar histology. Consistent with p53 allele loss, each mutation was found in the homo- or hemizygous state. One tumor showed a G to C transversion at p53 codon 213 (arginine to proline), and another showed deletion of the entire gene. The p53 mutations in cell lines included a codon 248 C to T transition (arginine to tryptophan) in RD and a codon 280 A to T transversion (arginine to serine) in RH30. The cell line CTR contained a 4-base pair deletion at codons 219/220 in exon 6 with resultant frame shift and premature termination in exon 7. These data support the role of diverse types of p53 mutations in the pathogenesis and/or progression of a significant proportion of cases of childhood RMS.
1 To whom requests for reprints should be addressed, at Division of Oncology, Department of Pediatrics, Wood Building/4th Floor, Children's Hospital of Philadelphia, 34th St. & Civic Center Blvd., Philadelphia, PA 19104.
Received 12/ 2/91. Accepted 2/10/92.
This article has been cited by other articles:
|
|
 |
|
  D. M. Langenau, M. D. Keefe, N. Y. Storer, J. R. Guyon, J. L. Kutok, X. Le, W. Goessling, D. S. Neuberg, L. M. Kunkel, and L. I. Zon Effects of RAS on the genesis of embryonal rhabdomyosarcoma Genes & Dev., June 1, 2007; 21(11): 1382 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Caldas, M P Holloway, B M Hall, S J Qualman, and R A Altura Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo J. Med. Genet., February 1, 2006; 43(2): 119 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Graham, C. Tucker, J. Creech, E. Favours, C. A. Billups, T. Liu, M. Fouladi, B. B. Freeman III, C. F. Stewart, and P. J. Houghton Evaluation of the Antitumor Efficacy, Pharmacokinetics, and Pharmacodynamics of the Histone Deacetylase Inhibitor Depsipeptide in Childhood Cancer Models In vivo Clin. Cancer Res., January 1, 2006; 12(1): 223 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Keller, B. R. Arenkiel, C. M. Coffin, N. El-Bardeesy, R. A. DePinho, and M. R. Capecchi Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function Genes & Dev., November 1, 2004; 18(21): 2614 - 2626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhang, S. Hu, D. E. Schofield, P. H. B. Sorensen, and T. J. Triche Selective Usage of D-Type Cyclins by Ewing's Tumors and Rhabdomyosarcomas Cancer Res., September 1, 2004; 64(17): 6026 - 6034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Schwartzenberg-Bar-Yoseph, M. Armoni, and E. Karnieli The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression Cancer Res., April 1, 2004; 64(7): 2627 - 2633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Armoni, M. J. Quon, G. Maor, S. Avigad, D. N. Shapiro, C. Harel, D. Esposito, Y. Goshen, I. Yaniv, and E. Karnieli PAX3/Forkhead Homolog in Rhabdomyosarcoma Oncoprotein Activates Glucose Transporter 4 Gene Expression in Vivo and in Vitro J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5312 - 5324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jaboin, J. Wild, H. Hamidi, C. Khanna, C. J. Kim, R. Robey, S. E. Bates, and C. J. Thiele MS-27-275, an Inhibitor of Histone Deacetylase, Has Marked in Vitro and in Vivo Antitumor Activity against Pediatric Solid Tumors Cancer Res., November 1, 2002; 62(21): 6108 - 6115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ito, T. Fukusato, T. Nemoto, H. Sekihara, Y. Seyama, and S. Kubota Coexpression of Glucose Transporter 1 and Matrix Metalloproteinase-2 in Human Cancers J Natl Cancer Inst, July 17, 2002; 94(14): 1080 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. B. Leonard, L. B. Travis, K. Addya, G. M. Dores, E. J. Holowaty, K. Bergfeldt, D. Malkin, B. A. Kohler, C. F. Lynch, T. Wiklund, et al. p53 Mutations in Leukemia and Myelodysplastic Syndrome after Ovarian Cancer Clin. Cancer Res., May 1, 2002; 8(5): 973 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Lewis, T. N. Truong, and M. A. Schwartz Integrins regulate the apoptotic response to DNA damage through modulation of p53 PNAS, March 19, 2002; 99(6): 3627 - 3632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Scholl, P. McLoughlin, E. Ehler, C. de Giovanni, and B. W. Schafer DRAL Is a p53-responsive Gene Whose Four and a Half LIM Domain Protein Product Induces Apoptosis J. Cell Biol., October 23, 2000; 151(3): 495 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mejia, A. Pellin, S. Navarro, V. Castel, and A. Llombart-Bosch A New Mutation of the p53 Gene in Human Neuroblastoma, Not Correlated with N-myc Amplification International Journal of Surgical Pathology, July 1, 1999; 7(3): 149 - 154. [Abstract] [PDF]
|
|
|
|
|
|
M. Bernasconi, A. Remppis, W. J. Fredericks, F. J. Rauscher III, and B. W. Schafer Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins PNAS, November 12, 1996; 93(23): 13164 - 13169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Grigorian, S. Andresen, E. Tulchinsky, M. Kriajevska, C. Carlberg, C. Kruse, M. Cohn, N. Ambartsumian, A. Christensen, G. Selivanova, et al. Tumor Suppressor p53 Protein Is a New Target for the Metastasis-associated Mts1/S100A4 Protein. FUNCTIONAL CONSEQUENCES OF THEIR INTERACTION J. Biol. Chem., June 15, 2001; 276(25): 22699 - 22708. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
